| Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): scale presentation and clinimetric testing results CG Goetz, BC Tilley, SR Shaftman, GT Stebbins, S Fahn, ... Movement disorders: official journal of the Movement Disorder Society 23 (15 …, 2008 | 6212 | 2008 |
| Genome-wide association study reveals genetic risk underlying Parkinson's disease J Simon-Sanchez, C Schulte, JM Bras, M Sharma, JR Gibbs, D Berg, ... Nature genetics 41 (12), 1308-1312, 2009 | 2183 | 2009 |
| Rotenone, paraquat, and Parkinson’s disease CM Tanner, F Kamel, GW Ross, JA Hoppin, SM Goldman, M Korell, ... Environmental health perspectives 119 (6), 866-872, 2011 | 1610 | 2011 |
| The Parkinson progression marker initiative (PPMI) K Marek, D Jennings, S Lasch, A Siderowf, C Tanner, T Simuni, C Coffey, ... Progress in neurobiology 95 (4), 629-635, 2011 | 1483 | 2011 |
| Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study CW Olanow, K Kieburtz, P Odin, AJ Espay, DG Standaert, HH Fernandez, ... The Lancet Neurology 13 (2), 141-149, 2014 | 718 | 2014 |
| Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial MS Okun, HH Fernandez, SS Wu, L Kirsch‐Darrow, D Bowers, F Bova, ... Annals of Neurology: Official Journal of the American Neurological …, 2009 | 597 | 2009 |
| Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group B Ravina, K Marder, HH Fernandez, JH Friedman, W McDonald, ... Movement Disorders 22 (8), 1061-1068, 2007 | 577 | 2007 |
| Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial P Ponikowski, BA Kirwan, SD Anker, T McDonagh, M Dorobantu, ... The Lancet 396 (10266), 1895-1904, 2020 | 558 | 2020 |
| Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers MS Okun, M Tagliati, M Pourfar, HH Fernandez, RL Rodriguez, ... Archives of neurology 62 (8), 1250-1255, 2005 | 508 | 2005 |
| Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data HC Fung, S Scholz, M Matarin, J Simón-Sánchez, D Hernandez, A Britton, ... The Lancet Neurology 5 (11), 911-916, 2006 | 467 | 2006 |
| Aspiration and swallowing in Parkinson disease and rehabilitation with EMST: a randomized trial MS Troche, MS Okun, JC Rosenbek, N Musson, HH Fernandez, ... Neurology 75 (21), 1912-1919, 2010 | 441 | 2010 |
| Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease JH Kang, DJ Irwin, AS Chen-Plotkin, A Siderowf, C Caspell, CS Coffey, ... JAMA neurology 70 (10), 1277-1287, 2013 | 419 | 2013 |
| Dissociating apathy and depression in Parkinson disease L Kirsch-Darrow, HF Fernandez, M Marsiske, MS Okun, D Bowers Neurology 67 (1), 33-38, 2006 | 387 | 2006 |
| A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease IH Richard, MP McDermott, R Kurlan, JM Lyness, PG Como, N Pearson, ... Neurology 78 (16), 1229-1236, 2012 | 381 | 2012 |
| The Parkinson's progression markers initiative (PPMI)–establishing a PD biomarker cohort K Marek, S Chowdhury, A Siderowf, S Lasch, CS Coffey, ... Annals of clinical and translational neurology 5 (12), 1460-1477, 2018 | 369 | 2018 |
| Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study B Ravina, M Putt, A Siderowf, JT Farrar, M Gillespie, A Crawley, ... Journal of Neurology, Neurosurgery & Psychiatry 76 (7), 934-939, 2005 | 349 | 2005 |
| Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors V Voon, M Pessiglione, C Brezing, C Gallea, HH Fernandez, RJ Dolan, ... Neuron 65 (1), 135-142, 2010 | 329 | 2010 |
| SNCA variants are associated with increased risk for multiple system atrophy SW Scholz, H Houlden, C Schulte, M Sharma, A Li, D Berg, A Melchers, ... Annals of Neurology: Official Journal of the American Neurological …, 2009 | 318 | 2009 |
| A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit MF Beal, D Oakes, I Shoulson, C Henchcliffe, WR Galpern, R Haas, ... JAMA neurology 71 (5), 543-552, 2014 | 292 | 2014 |
| Pathophysiology and treatment of psychosis in Parkinson’s disease: a review LB Zahodne, HH Fernandez Drugs & aging 25, 665-682, 2008 | 278 | 2008 |
